Drug intelligence / Profile preview

AUY922 + trastuzumab

Development stage: Unknown
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

AUY922 + trastuzumab is a combination therapy that pairs the HSP90 inhibitor AUY922 with the HER2-targeting monoclonal antibody trastuzumab. AUY922 works by inhibiting heat shock protein 90 (HSP90), which enables the activation of many client proteins including HER2. This inhibition leads to degradation of oncogenic proteins. The combination has shown synergistic activity in HER2-positive cancer models, particularly in trastuzumab-resistant settings. The rationale for this combination is based on the ability of HSP90 inhibition to overcome trastuzumab resistance mechanisms in HER2-positive cancers.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)HSP90 (Heat shock protein 90 chaperone complex)

Beyond the preview

Go deeper on AUY922 + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUY922 + trastuzumab.

Explore the full profile